Trials
6 active
9 in total · 4 in the EU
Targets
—
None known yet
What this is
- How it works
- BAFF/APRIL dual inhibitor (TACI-Fc fusion protein)
- How it’s given
- “Placebo matched to Povetacicept subcutaneous injection administration.”In the company’s words, NCT06564142 on ClinicalTrials.gov
- Tested for
- Immunoglobulin A Nephropathy (4 trials), Primary Membranous Nephropathy, Myasthenia Gravis, Generalized, Lupus Nephritis, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Main trialPhase 3
- “The purpose of this study is to evaluate participant treatment experience with Povetacicept injection administered via autoinjector relative to Sibeprenlimab injection administered via prefilled syringe (PFS), and to assess the safety and tolerability of Povetacicept in participants with Immunoglobulin A nephropathy (IgAN).”In the company’s words, NCT07890909 on ClinicalTrials.gov
- Other names
- ALPN-303
Other drugs for Immunoglobulin A Nephropathy
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- SC0062Biocity Biopharmaceutics Co., Ltd. · Phase 3
- FelzartamabBiogen · Phase 3
- ZigakibartNovartis · Phase 3
- HRS-5965Hengrui · Phase 3
- IptacopanNovartis · Phase 3
Coming up6
- 12 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Jan 2028Phase 3 trial completes · ClinicalTrials.gov
- 2 Mar 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 2 Mar 2029Phase 2 trial completes · ClinicalTrials.gov
- 27 Jun 2029Phase 2/3 trial completes · ClinicalTrials.gov
- 28 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 18 NovCompletion date moved: 2028-12-29 to 2029-06-27 · ClinicalTrials.gov NCT07204275
- 17 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07890909
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 12 Dec 2027 | A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe | |
| Phase 3Active, not recruiting | 30 Jan 2028 | Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) | |
| Phase 3Enrolling by invitation | 28 Dec 2029 | A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy | |
| Phase 2/3Recruiting | 27 Jun 2029 | Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) | |
| Phase 2Active, not recruiting | 2 Mar 2029 | A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis | |
| Phase 1/2Active, not recruiting | 2 Mar 2028 | An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases | |
| Phase 1/2Completed | 12 Aug 2026 | An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) | |
| Phase 1Completed | 27 Feb 2023 | A Study of ALPN-303 in Adult Healthy Volunteers | |
| Phase 1Completed | 19 Aug 2025 | A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026